TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01622439
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vill be given intravenously, 750 mg/m2, every second or third week depending on cycle length (14 or 21 days) for a total of 6 cycles.
Study: NCT01622439
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vill be given intravenously, 50 mg/m2, every second or third week depending on cycle length (14 or 21 days), for a total of 6 cycles.
Study: NCT03284463
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is administered with a loading dose of 1.25 mg within 10 hours of stroke onset, orally or through gastric tube, followed by 0.625 mg every 8 hour for 5 days.
Study: NCT01791244
Drug: Rebif®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01468389
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 900-1000mg/m2 bid, days 1-14, every 3 weeks
Study: NCT01468389
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dosing schedule: 900-1000mg/m2 bid, days 1-14, every 3 weeks Maintenance dosing schedule: 1000-1250mg/m2 bid, days 1-14, every 3 weeks
Study: NCT01691079
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled placebo administered before exercise.
Study: NCT00445315
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04139434
Drug: LP-108
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the dose escalation phase, LP-108 will be given once daily at the following dose levels: 100 mg QD, 200 mg QD, 400 mg QD, 600 mg QD, 800 mg QD, 1000 mg QD.
Study: NCT03092726
Drug: ASP8062
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP8062 30 mg was administered orally as a single daily dose, taken preferably in the morning with or without food.
Study: NCT03092726
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was administered orally as a single daily dose, taken preferably in the morning with or without food.
Study: NCT02639975
Drug: PBF-677
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily oral administration
Study: NCT02639975
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily oral administration
Study: NCT03443661
Drug: FOLFOXIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxaliplatin 85 mg/m2 irinotecan 150 mg/m2, 5FU 2,400 mg/m2 by 46 h infusion repeated at 2week intervals
Study: NCT00603954
Drug: Conditioning regimen:TLI (8 Gy) + ATG
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLI 8 Gy + ATG (Thymoglobulin) 7.5 mg/kg
Study: NCT03191981
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment for all patients will be with cyclophosphamide, lenalidomide and pembrolizumab at fixed doses.
Study: NCT02117752
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patches containing normal saline (Negative Control) will be applied to the skin.
Study: NCT02520726
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched encapsulated placebo from 1-4 capsules daily
Study: NCT02713126
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered orally or inhaled, taken every 4 hours or 3 times per day during waking hours for 12 weeks
Study: NCT00697502
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine (XELODA) is supplied as biconvex, oblong film-coated tablets for oral administration and will be obtained from NUH Cancer Centre pharmacy.~Each light peach-colored tablet contains 150 mg capecitabine and each peach-colored tablet contains 500 mg capecitabine. Capecitabine is to be administered orally within 30 minutes after the end of a meal (breakfast, dinner). Tablets should be swallowed with about 200 mL of water (not fruit juices). Capecitabine will be administered for 14 days followed by a 7 day rest period.
Study: NCT03912831
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously.
Study: NCT01460667
Drug: IV acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV acetaminophen 1000 mg (100 mL) every 6 hours over 30 hours
Study: NCT01657604
Drug: Peginterferon α2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive nilotinib 300 mg BID given as two 150 mg capsules twice daily with at a starting target dose of 30μg/week. After confirmed MMR or at least 24 mo. after start of therapy, maintenance therapy (nilotinib will be discontinued) will start for a study duration of up to 5 years.
Study: NCT04335617
Drug: MMPF (Micronized purified Flavonoid-Fraction)
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mg film-coated tablet, oral route, tablets should be taken at meal times. 4-day course of 6 tablets daily, followed by 4 tablets over the next 3 days followed by 2 tablets daily, one at midday and one in the evening
Study: NCT03657030
Drug: CVN424
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAD / MAD
Study: NCT03657030
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04499755
Drug: Nucleo CMP Forte
Normalized name: Erythroped Forte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleo CMP Forte twice daily for 6 weeks
Study: NCT00738322
Drug: AZD1305
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for iv infusion, single dose
Study: NCT00738322
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl solution for iv infusion, single dose
Study: NCT00391196
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects receive placebo plus non-pharmacological weight loss program.
Study: NCT02055872
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01052792
Drug: Naproxen Sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen Sodium Tablets 550 mg
Study: NCT00292942
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannitol (200 mg/vial) diluted in Phosphate Buffer and given IV in equivalent volume by subject's weight.
Study: NCT02774460
Drug: Zestril®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment step up: 1-2 weeks (10 mg tablet) Target dose: 5-7 weeks (20 mg tablet)
Study: NCT02774460
Drug: Atacand®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment step up: 1-2 weeks (8 mg tablet) Target dose: 5-7 weeks (16 mg tablet)
Study: NCT02774460
Drug: Norvasc®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment step up: 1-2 weeks (5 mg tablet) Target dose: 5-7 weeks (10 mg tablet)
Study: NCT02774460
Drug: Treatment X
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient receives all four treatments, and in addition repeats two of the treatments, labeled X and Y. The repeated arms will be given with the same duration and dosing as the other arms.
Study: NCT02774460
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an unblinded placebo run-in which we use to generate baseline values. Each patient will initiate their participation with these 2 weeks of placebo treatment, taking 1 capsule daily.
Study: NCT03613740
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention will be administered 30 minutes before breakfast.
Study: NCT00268723
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo MDI QID
Study: NCT00625131
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment placebo transdermal patch
Study: NCT00771914
Drug: Both Aspirin and Lovaza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovaza 4 grams plus aspirin 81 mg
Study: NCT02167958
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pre-transplant~Cy 14.5 mg/kg/day will be administered as a 1-2 hour intravenous infusion with a high volume fluid flush on Days -6 and -5. Cy will be dosed according to the recipient's actual body weight unless the patient weighs more than 125% of IBW, in which case the drug will be dosed according to the adjusted IBW~Post-transplant~Hydration prior to cyclophosphamide may be given according to Standard Practice Guidelines.~Cyclophosphamide \[50mg/kg\] will be given on Day 3 post-transplant (between 60 and 72 hours after marrow infusion) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cy will be dosed according to the recipient's actual body weight unless the patient weighs more than 125% of IBW, in which case the drug will be dosed according to the adjusted IBW. Cyclophosphamide will be given as an IV infusion over 1-2 hours.~.
Study: NCT03771755
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 mg IV - Ibuprofen every 6 hours. In case required - followed with Morphine (PCA) 1-2 mg every 5 minutes
Study: NCT03771755
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mg IV Acetaminophen every 6 hours. In case required - followed with Morphine (PCA) 1-2 mg every 5 minutes
Study: NCT01636765
Drug: No Intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intervention.
Study: NCT01046136
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: bid 7 days
Study: NCT01266876
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo two SC injections in the abdomen only.
Study: NCT00853112
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet form, single dose (Day 1)
Study: NCT02058108
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients of any age and weight \< 30kg: placebo oral solution corresponding to weight (kg) x1mL, p.o. once daily Patients \< 12 years old and weight ≥ 30kg: placebo oral solution corresponding to 30 mL p.o. once daily Patients ≥ 12 years old and weight ≥ 30kg: placebo tablet, corresponding to 1 tablet p.o. once daily
Study: NCT02561273
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02561273
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02051764
Drug: Florbetapir F 18
Normalized name: Florbetapir F 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: 370 megabecquerel (MBq) IV single-dose
Study: NCT00654667
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, no active drug, take 5 capsules by mouth daily for one month
Study: NCT02249338
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01075243
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03593902
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A medication used as chemotherapy and to suppress the immune system
Study: NCT00334880
Drug: NRP104
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00822614
Drug: Fentanyl TAIFUN
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Inhalation of Fentanyl via TAIFUN inhaler
Study: NCT00822614
Drug: Opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current optimized BTP treatment
Study: NCT03600909
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arms A, B and C - Cytoxan will be given as a 1-2 hour infusion for 4 days. The dose will be adjusted according to patients ideal body weight for obese patients.
Study: NCT00545740
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD orally
Study: NCT01540110
Drug: Neoadjuvant Docetaxel and Cyclophosphamide
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5.1.1 Docetaxel Docetaxel at a dose of 75 mg/m2 will be administered by intravenous infusion over 90 minutes (AFTER completion of cyclosphosphamide 600 mg/m2) on D1 every 21 days for 6 cycles using nonpolyvinylchloride tubing.~Standard premedication with oral dexamethasone 8 mg bd on D-1, D1 and D2 will be administered. Alternatively, intravenous dexamethasone 8 mg before docetaxel followed by oral dexamethasone 8 mg bd on D1 and D2 can be given.~Routine prevention of chemotherapy induced emesis will be administered (see 5.2.2)~5.1.2 Cyclophosphamide~Cyclophosphamide 600 mg/m2 by slow intravenous infusion over 10 minutes (BEFORE docetaxel) will be administered every 21 days for 6 cycles.~No premedications are required except for routine prevention of chemotherapy induced emesis (see 5.2.2)
Study: NCT00641979
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00554424
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mls of normal saline solution, 10mls injected each side into upper vagina under ultrasound guidance, immediately prior to ultrasound guided transvaginal oocyte retrieval from each ovary
Study: NCT02765100
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline 100 mg twice a day
Study: NCT00808405
Drug: matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo taken orally three times daily for 5 days.
Study: NCT03605667
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral matching placebo will be given daily for up to 48 weeks
Study: NCT04686461
Drug: Nigella sativa seeds extract containing ointment intervention
Normalized name: Nigella sativa seed extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nigella sativa seeds extract containing ointment Nigella sativa seed extract, bee wax, white petrolatum, stearyl alcohol
Study: NCT00980187
Drug: Indapamide
Normalized name: Indapamide
DrugBank: Indapamide (DB00808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.5 mg SR, orally, once a day,with Quinapril 10-40 mg, 6 months
Study: NCT04653506
Drug: Ibuprofen 400 mg
Normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Women participating in the study will receive postpartum analgesia immediately while reporting pain requiring analgesia, by envelope contains paracetamol 1000 mg or ibuprofen 400 mg
Study: NCT05953675
Drug: Ethanol 70%
Normalized name: Ethanol 70% Topical application Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once a week, the catheter will be closed with 3 mL ethanol 70% lock-solution after a completed hemodialysis. The fluid will stay in the catheter until next hemodialysis (ca. 48 hours). The fluid will be aspirated before the hemodialysis. Standard lock-solution of isotonic saline with heparin will be used for the remaining two hemodialysis procedures of the week.
Study: NCT05066802
Drug: neoadjuvant modified FOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxaliplatin 85 mg/m2 D1 + leucovorin 400mg/m2 D1 + irinotecan 150 mg/m2 D1 + 5-FU 2,000 mg/m2 42\~46h continuous infusion, every other week for 6 cycles (12 weeks) before surgery.
Study: NCT05953675
Drug: Isotonic saline with heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard procedure of isotonic saline used as lock-fluid after completed hemodialysis.
Study: NCT02111421
Drug: Dexmetomidine 02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial dose of dexmedetomidine was 1.0 μg/kg, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last four turning points,as soon as the spinal anesthesia
Study: NCT03926286
Drug: FMP-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: FMP-30 containing frozen human fecal microbiota administered as (3) units of FMP30 enema on Day 0 and Week1
Study: NCT03636555
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution (contained all the ingredients in Syntocinon Spray except for oxytocin) will be given as an intranasal spray twice daily (10 insufflations, 1.0 mL/dose) for 12 weeks
Study: NCT00149968
Drug: Enteric-Coated Mycophenolate Sodium (EC-MPS)
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient on MMF treatment completes questionnaire and switch to equimolar doses of Myfortic. Maximum daily dose 1440 mg
Study: NCT04392960
Drug: [18F]Florbetaben
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will undergo on the same day:~* 18F-florbetaben PET-CT scans. The dose to be injected intravenously (6 second/mL) will be 370 MBq (for a 70 Kg patient);~* standard assessment of clonal and organ disease;~* echocardiography;~* cardiac magnetic resonance.~All the patients will undergo those evaluations at baseline and 6 months after treatment initiation.
Study: NCT01900249
Drug: R348 Ophthalmic Solution, 0.2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: R348 Ophthalmic Solution, 0.2% 1 drop per eye twice a day for 12 weeks.
Study: NCT01900249
Drug: R348 Ophthalmic Solution, 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: R348 Ophthalmic Solution, 0.5% 1 drop per eye twice a day for 12 weeks.
Study: NCT01900249
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Ophthalmic Solution 1 drop per eye twice a day for 12 weeks.
Study: NCT02114528
Drug: Antiarrhythmic Drug Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Either one or more of the following antiarrhythmic drugs: sotalol, mexiletine, procainamide, or amiodarone.
Study: NCT02291094
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in remifentanil group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous remifentanil infusion of 0,1 mcg/kg/min.
Study: NCT00792922
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Comparison of community coverage rate
Study: NCT02433626
Drug: COTI2
Normalized name: Coti2
Approvals — FDA: no, EMA: no, PMDA: no
Description: COTI-2 is a third generation thiosemicarbazone.
Study: NCT00792922
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Comparison of coverage levels at baseline treatment followed by annual treatment if prevalence of trachoma is \>5%. In Niger, there will be a comparison of coverage levels in everyone versus in children ages twelve and under who are treated every 6-months.
Study: NCT03389659
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 5 pills po. qd continue to disease progression
Study: NCT04587505
Drug: Continuous intravenous analgesia
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 100 mg in the first hour followed by tramadol 300 mg continuously for the next 24 hours.
Study: NCT02189772
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive drug
Study: NCT00388128
Drug: Caffeine 6mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules of caffeine 6 mg/kg, taken orally at each test. Before and after treadmill testing
Study: NCT00584948
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Week 1: Take 5mg tab every morning. Week 2: Take 5mg tab every morning and evening. Week 3: Take 10mg tab in the morning and 5 mg in the evening. Week 4: Take 10 mg tab in the morning and evening, and remain on this dose through the remainder of the study.
Study: NCT02620631
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects receive intrathecal, preservative-free normal saline pre-operatively in conjunction with post-operative PCA morphine
Study: NCT04312061
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral placebo tablet given 1 hour before LNG-IUD insertion
Study: NCT01988649
Drug: Placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of normal saline intranasally.
Study: NCT02914158
Drug: Aromatase Inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01077986
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine will be administered for 14 days in a 3 weekly cycle, starting on day 8.
Study: NCT03953001
Drug: 2% Lidocaine with 1:50,000 epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local Dental anesthetic infiltration
Study: NCT02079506
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01673529
Drug: SB705498
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1%, 3% and 5% (w/w) of SB705498 will be used in part A of the study. One dose will then be selected based on criteria explained in the protocol for use in Part B of the study.
Study: NCT01159275
Drug: Aluvia and Generic LPV/r (pharmacokinetics)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First Pediatric Aluvia® 200/50 mg BID, then cross over to Generic LPV/r 200/50 mg BID
Study: NCT03968588
Drug: Tacrolimus(reduced), Mycophenolate mofetil(standard)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tacrolimus target trough blood level: 3\~8ng/mL MMF dose: 1.5\~2g/d
Study: NCT03968588
Drug: Tacrolimus(standard), Mycophenolate mofetil(reduced)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tacrolimus target trough blood level: 5\~15ng/mL MMF dose: 0.5\~1g/d
Study: NCT02014831
Drug: TIP
Normalized name: Q-Tips
Approvals — FDA: no, EMA: no, PMDA: no
Description: The TIP combination of treatments will be administered on specific days within a 21-days-cycle and for a maximum of 6 cycles as follow :~PACLITAXEL I.V infusion of 175 mg/m2, for 3 hours, on Day 1 of the cycle.~IFOSFAMIDE I.V infusion of 1200 mg/m2, for 2 hours, on Day 1, Day 2, Day 3 of the cycle.~CISPLATINE I.V infusion of 25 mg/m2, for 1 hour, on Day 1, Day 2, Day 3.~In case of documented toxicities, 2 drugs doses reductions are allowed according specific algorithms indicated in protocol
Study: NCT00470223
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes